<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02682849</url>
  </required_header>
  <id_info>
    <org_study_id>15-006388</org_study_id>
    <nct_id>NCT02682849</nct_id>
  </id_info>
  <brief_title>Active Clearance Technology (ACT) Registry</brief_title>
  <official_title>Prevention of Retained-Blood Outcomes With Active Clearance Technology- The ACT Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John M. Stulak</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of the PleuraFlow® Active
      Clearance Technology™ (ACT) System in the management of blood evacuation after cardiac
      surgery.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 10, 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Number of interventions to Treat Retained Blood Syndrome</measure>
    <time_frame>Discharge from operating room for index-surgery through hospital discharge - approximate 30 days</time_frame>
    <description>Retained Blood Syndrome (RBS) is defined by a composite endpoint of specific reoperation for bleeding, pericardial effusion, and hemothorax.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of episodes of new on set of post operative atrial fibrillations (POAS)</measure>
    <time_frame>30 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of readmissions for any diagnosis of RBS or POAS re-occurrences</measure>
    <time_frame>30 day</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">500</enrollment>
  <condition>Retained Blood Syndrome</condition>
  <arm_group>
    <arm_group_label>Retrospective cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective PleuralFlow cohort</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The control arm consists of a cohort of matched cardiac surgery patients with data entered
        over the preceding 12 to 24-month period. The site will consecutively enroll a cohort of
        cardiac surgery patients in the treatment arm.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female subjects 18 years of age or older who received a PleuraFlow System
             following heart surgery.

          2. Patient undergoing cardiac surgery via sternotomy

        Exclusion Criteria:

          1. Robotic surgery

          2. Any access via thoracotomy

          3. Any condition deemed inappropriate for inclusion by the investigators.

          4. Intolerance to implantable silicone materials.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Stulak, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 11, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2016</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>John M. Stulak</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

